Ironwood Pharmaceuticals, Inc. (IRWD)
|52 Week Range||8.07-12.66|
|1y Target Est||-|
|DCF Unlevered||IRWD DCF ->|
|DCF Levered||IRWD LDCF ->|
|Debt / Equity||-227.42%||Sell|
Upgrades & Downgrades
Latest IRWD news
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
10 November 2023
Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript
9 November 2023
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executi...
Ironwood Pharmaceuticals: The Right Play Now
27 October 2023
Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved fo...
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functio...
5 October 2023
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric...
Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?
20 September 2023
Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro...
Ironwood: Pipeline Progresses As FDA Approves LINZESS
26 August 2023
Ironwood Pharmaceuticals specializes in the development and commercialization of drugs for gastrointestinal diseases, with a focus on conditions like irritable bowel syndrome and chronic constipation....
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
9 August 2023
Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.
3 Lost Formula Stocks to Consider for the 2nd Half of 2023
7 July 2023
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.
Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion
13 June 2023
Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.